Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) (2019)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1093/annonc/mdz061
- Subjects: NEOPLASIAS MAMÁRIAS; METÁSTASE NEOPLÁSICA; RESULTADO DE TRATAMENTO; QUIMIOTERAPIA COMBINADA; ANTINEOPLÁSICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Annals of oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 30, n. 5, p. 766-773, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: publisher-specific-oa
-
ABNT
BACHELOT, T et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, v. 30, n. 5, p. 766-773, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdz061. Acesso em: 19 abr. 2024. -
APA
Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., et al. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of oncology, 30( 5), 766-773. doi:10.1093/annonc/mdz061 -
NLM
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1093/annonc/mdz061 -
Vancouver
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-shimon S, Wardley A, Merot J-L, Hegg R. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [Internet]. Annals of oncology. 2019 ; 30( 5): 766-773.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1093/annonc/mdz061 - Cancer de ovario
- Vias e esquemas de administração dos hormônios esteróides
- Eficácia, tolerabilidade e controle de ciclo de um contraceptivo oral sem estrogênio contendo 30 mcg de levonorgestrel (minipílula)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
- First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial
- Galactorreia: sindrome hiperprolactinemica
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
Informações sobre o DOI: 10.1093/annonc/mdz061 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
